SCHEMBL2784791

SCHEMBL2784791

Oc1ccc(Oc2ccccc2)cc1I

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 4/20 0.54
NR1H2 P55055 1/20 0.54
BAX Q07812 1/20 0.54
THRB P10828 6/20 0.51
THRA P10827 5/20 0.51
PCNA P12004 5/20 0.51
LMNA P02545 3/20 0.51
POLB P06746 2/20 0.51
HIF1A Q16665 2/20 0.51
ABCB11 O95342 2/20 0.51
GABRA1 P14867 2/20 0.51
PPARG P37231 2/20 0.51
GABRA2 P47869 2/20 0.51
GABRB2 P47870 2/20 0.51
CYP1A2 P05177 1/20 0.51
PGR P06401 1/20 0.51
CHRM2 P08172 1/20 0.51
HTR1A P08908 1/20 0.51
ADRA2A P08913 1/20 0.51
ADORA3 P0DMS8 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14575001 0.89 THRB (0.54) THRBTHRAPCNALMNAPOLB
SCHEMBL14575487 0.86 MEN1 (0.58) LTA4HNR1H2BAXTHRBTHRA
SCHEMBL24407712 0.82 THRB (0.54) THRBTHRAPCNALMNAPOLB
SCHEMBL14616574 0.82 THRB (0.49) THRBTHRAPCNALMNAPOLB
SCHEMBL11645394 0.81 LTA4H (0.67) LTA4HNR1H2BAXTSHRMEN1
SCHEMBL6567350 0.78 THRB (0.58) THRBTHRAPCNALMNAPOLB
SCHEMBL5380053 0.78 THRA (0.56) LTA4HNR1H2BAXTHRBTHRA
SCHEMBL5991731 0.78 THRA (0.56) LTA4HNR1H2BAXTHRBTHRA
SCHEMBL24407715 0.77 THRB (0.52) THRBTHRAPCNALMNAPOLB
SCHEMBL4101422 0.76 LTA4H (0.54) LTA4HNR1H2BAXTSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-29 US disclosed
EP-4229045-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute Inc. (US) 2023-08-23 EP disclosed
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed
EP-2258694-A1 Amines as histamine-3 receptor ligands and their therapeutic applications Abbott Laboratories (US) 2010-12-08 EP disclosed
US-7538138-B2 Amines as histamine-3 receptor ligands and their therapeutic applications ABBOTT LABORATORIES (US) 2009-05-26 US disclosed
US-6969730-B2 Amines as histamine-3 receptor ligands and their therapeutic applications ABBOTT LABORATORIES (US) 2005-11-29 US disclosed
US-20050192277-A1 Novel amines as histamine-3 receptor ligands and their therapeutic applications ABBVIE INC. 2005-09-01 US disclosed
EP-1370546-A2 NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS Abbott Laboratories (US) 2003-12-17 EP disclosed
US-20020169188-A1 Novel amines as histamine-3 receptor ligands and their therapeutic applications ABBVIE INC. 2002-11-14 US disclosed
WO-2002074758-A2 NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2002-09-26 WO disclosed
US-5169984-A One step bromoacetylation of 3,3',5-triodo-l-thyronine with bromoacetyl bromide THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1992-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A LTA4H 1809/4885NR1H2 580/4885BAX 2946/4885
US-20050192277-A1 Novel amines as histamine-3 receptor ligands and their therapeutic applications HRH3, HRH4, HRH2 LTA4H 462/4885NR1H2 524/4885BAX 3463/4885
US-20020169188-A1 Novel amines as histamine-3 receptor ligands and their therapeutic applications HRH3, HRH4, HRH1 LTA4H 479/4885NR1H2 484/4885BAX 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.